Search

Displaying results 1871 - 1880 of 10000 in total
  1. Drug

    Vinflunine

    go.drugbank.com/drugs/DB11641
    ApprovedInvestigational

    Like other vinca agents, vinflunine is an anti-mitotic agent that induces a cell cycle arrest at the G2/M phase and promotes cell death via apoptosis [L1396]. … Vinflunine is a third-generation member of the vinca alkaloid family with anti-tumour actions. It was first described in 1998 at the Pierre Fabre research center in France.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  2. Drug

    2,2'-Dibenzothiazyl disulfide

    go.drugbank.com/drugs/DB14201
    Approved

    2,2'-Dibenzothiazyl disulfide is an accelerator used in the processing process for natural and synthetic rubber and plastic regeneration. It is also a known allergen and dermatological sensitizer. … Sensitivity to 2,2'-Dibenzothiazyl disulfide may be identified with a clinical patch test.

  3. Drug

    Hydroxycitronellal

    go.drugbank.com/drugs/DB14187
    Approved

    Hydroxycitronellal has also been shown to be a dermatologic irritant and allergen, and as a result commercially available products are restricted by the International Fragrance Association (IFRA) to contain … Hydroxycitronellal is a synthetic fragrance that is widely used in many cosmetics and hygiene products such as deodorants, soaps, antiseptics, and other household items.

    Synonyms: 3,7-dimethyl-7-hydroxyoctan-1-al
  4. Target

    Prostaglandin E2 Receptors

    go.drugbank.com/bio_entities/BE0010100
    TargetHumans

    Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. … Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(q) proteins which activate a phosphatidylinositol-calcium second messenger system.

    Polypeptides: Prostaglandin E2 receptor EP1 subtype, Prostaglandin E2 receptor EP2 subtypeSynonyms: PGE receptor EP1 subtype, Prostanoid EP1 receptor
  5. Drug

    Camizestrant

    go.drugbank.com/drugs/DB19218
    ApprovedInvestigational

    Camizestrant is an oral selective estrogen receptor degrader (SERD) and estrogen receptor (ER) antagonist used in combination with a CDK4/6 inhibitor to treat hormone receptor-positive, HER2-negative locally … [L64094,L64107] In pre- or peri-menopausal women and in men, camizestrant plus a CDK4/6 inhibitor is combined with an LHRH agonist or antagonist.

    Categories: Estrogen Receptor Antagonists, Selective Estrogen Receptor Degraders
  6. Drug

    Nalbuphine

    go.drugbank.com/drugs/DB00844
    ApprovedInvestigational

    A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. … Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States.

  7. Drug

    Trandolapril

    go.drugbank.com/drugs/DB00519
    ApprovedInvestigational

    Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment … ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS).

  8. Drug

    Pertuzumab

    go.drugbank.com/drugs/DB06366
    ApprovedInvestigational

    Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). … Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.

    Categories: HER2 Receptor Antagonists, Receptor, ErbB-2, antagonists & inhibitors
  9. Drug

    Decitabine

    go.drugbank.com/drugs/DB01262
    ApprovedInvestigational

    [L14962] It is also available as an oral combination product together with the cytidine deaminase inhibitor [cedazuridine]. … Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis.

  10. Drug

    Bicisate

    go.drugbank.com/drugs/DB11164
    Approved

    Bicisate, also known as ethyl cysteinate dimer (ECD), is a N,N'-1,2-ethylene-di-yl-bis-L-cysteinate diethyl ester. … [A32374] The complex of bicisate and technetium Tc99m as a kit was developed by Lantheus Medcl and FDA-approved on November 23, 1994.[L2029]